Despite FDA hold, Epizyme’s tazemetostat posts positive interim data

Despite an FDA hold on its lead program, tazemetostat, Epizyme is trucking along, reporting interim data for a phase 2 trial in follicular lymphoma, working to resolve the hold and looking to file an NDA for a solid tumor indication later this year.